A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Inclusion Criteria: * Adults 18 to 65 years of age * CHC infection as shown on enzyme-linked immunosorbent assay (ELISA) and radioimmunoblot assay (RIBA) or quantifiable hepatitis C virus (HCV) ribonucleic acid (RNA) greater than (\>) 2000 copies per milliliter (copies/mL) * Use of two forms of contraception during study and 6 months after the study in both men and women * Normal renal function (creatinine clearance \[CrCl\] \>80 milliliters per minute \[mL/min\]), moderate renal impairment (CrCl 30 to 50 mL/min), severe renal impairment (CrCl less than \[\<\] 30 mL/min), or ESRD requiring hemodialysis * Patients with ESRD must have been undergoing hemodialysis for at least 2 months Exclusion Criteria: * Women who are pregnant or breastfeeding * Male partners of women who are pregnant * Conditions associated with decompensated and/or chronic liver disease * Human immunodeficiency virus (HIV) infection * Interferon or ribavirin treatment within the previous 3 months * Poor hematologic function, including unstable hemoglobin * Significant comorbidity or severe illness which would make the participant unsuitable for the study * Acute renal failure